Arcadia Biosciences, Inc. (RKDA) Operating margin 2017–2025
Arcadia Biosciences, Inc. (RKDA) operating margin by fiscal year — reported operating income divided by reported revenue.
-51.5%FY2025 · since FY2017: -355.6% → -51.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -51.5% | +20.8 pp |
| FY2024 | -72.3% | +64.7 pp |
| FY2023 | -137.0% | +51.8 pp |
| FY2022 | -188.8% | +335.2 pp |
| FY2021 | -524.0% | -364.9 pp |
| FY2020 | -159.0% | +1498.9 pp |
| FY2019 | -1657.9% | -505.6 pp |
| FY2018 | -1152.3% | -796.8 pp |
| FY2017 | -355.6% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More RKDA financial trends
RKDA RevenueRKDA Net incomeRKDA Net marginRKDA Gross profitRKDA Gross marginRKDA Operating incomeRKDA Operating cash flowRKDA Free cash flowRKDA Capital expendituresRKDA Return on equityRKDA Stock buybacksRKDA Dividends paidRKDA Total assetsRKDA Total liabilitiesRKDA Shareholders’ equityRKDA overview →